Clinical Trials Browser

Phase 2 × Head and Neck Neoplasms × durvalumab × Clear all

NCT03691714 2026-06-01

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

35 enrolled 13 charts

Head and Neck Neoplasms, Neoplasm Metastasis

NCT06446570 2024-06-06

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03292250 2022-03-29

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

Phase 2 Completed

DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT02207530 2020-09-29

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

112 enrolled 20 charts

Head and Neck Neoplasms, Recurrence

NCT02319044 2020-09-29

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

267 enrolled 27 charts

Head and Neck Neoplasms, Recurrence